Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: Results of a phase 2 consortium study

The Lancet Oncology

Volumn 11, Issue 10, 2010, Pages 962-972

  Bible, Keith C ^a   Suman, Vera J ^a   Molina, Julian R ^a   Smallridge, Robert C ^b   Maples, William J ^b   Menefee, Michael E ^b   Rubin, Joseph ^a   Sideras, Kostandinos ^a   Morris, John C ^a   McIver, Bryan ^a   Burton, Jill K ^a   Webster, Kevin P ^a   Bieber, Carolyn ^b   Traynor, Anne M ^c   Flynn, Patrick J ^d   Goh, Boon Cher ^e   Tang, Hui ^a   Ivy, Susan Percy ^f   Erlichman, Charles ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF WISCONSIN   (United States)

^d Minnesota Oncology and Hematology Professional Association   (United States)

^e NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; PAZOPANIB; RADIOACTIVE IODINE; UNCLASSIFIED DRUG; VOTRIENT; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; SULFONAMIDE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ACUTE CHOLECYSTITIS; ADRENAL INSUFFICIENCY; ADULT; ADVANCED CANCER; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTHRALGIA; ARTHRITIS; ARTHROPATHY; ARTICLE; BACKACHE; BLURRED VISION; BRAIN HEMORRHAGE; CANCER RADIOTHERAPY; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COLITIS; COLON PERFORATION; CONSTIPATION; COUGHING; DIARRHEA; DIPLOPIA; DISEASE COURSE; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; DYSPHAGIA; EPIPHORA; EPISTAXIS; EXTRAPYRAMIDAL SYNDROME; FATIGUE; FEMALE; FLATULENCE; FLUSHING; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HAIR DISCOLORATION; HEART ATRIUM FIBRILLATION; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERPIGMENTATION; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOALBUMINEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; HYPOPIGMENTATION; HYPOTENSION; INSOMNIA; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; METASTASIS; MOUTH CAVITY; MOUTH PAIN; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; MYALGIA; NAIL; NAUSEA; NEURALGIA; NEUTROPENIA; OLFACTORY NERVE DISEASE; ORAL BLEEDING; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PETECHIA; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PHOTOPHOBIA; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; SIDE EFFECT; SKIN BRUISING; SKIN BURNING SENSATION; SKIN MANIFESTATION; SKIN PAIN; SKIN TOXICITY; SORE THROAT; SWEATING; TASTE DISORDER; THORAX PAIN; THROMBOCYTOPENIA; THYROID CANCER; TRACHEITIS; URINARY FREQUENCY; VAGINA BLEEDING; VOICE; VOMITING; WEIGHT REDUCTION; XEROSTOMIA; CELL DIFFERENTIATION; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; RADIOGRAPHY; SECONDARY; THYROID NEOPLASMS; TIME; TREATMENT FAILURE; UNITED STATES; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RADIOPHARMACEUTICALS; SULFONAMIDES; THYROID NEOPLASMS; TIME FACTORS; TREATMENT FAILURE; UNITED STATES; YOUNG ADULT;

EID: 77957359933     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70203-5     Document Type: Article

References (29)

1. Cancer facts & figures 2009 2009, American Cancer Society, American Cancer Society, Atlanta.
2. Chen AY, Jemal A, Ward EM Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer 2009, 115:3801-3807.
3. Enewold L, Zhu K, Ron E, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev 2009, 18:784-791.
4. Hayat MJ, Howlader N, Reichman ME, Edwards BK Cancer statistics, trends, and multiple primary cancer analyses from the surveillance, epidemiology, and end results (SEER) program. Oncologist 2007, 12:20-37.
5. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
6. Al-Eid HS, Arteh SO Cancer incidence report Saudi Arabia 2003 2003, Kingdom of Saudi Arabia Ministry of Health National Cancer Registry, Riyadh.
7. Baudin E, Schlumberger M New therapeutic approaches for metastatic thyroid carcinoma. Lancet Oncol 2007, 8:148-156.
8. Sherman SI Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J Clin Endocrinol Metab 2009, 94:1493-1499.
9. Kumar R, Knick VB, Rudolph SK, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007, 6:2012-2021.
10. Hurwitz HI, Dowlati A, Saini S, et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 2009, 15:4220-4227.
11. Cohen EE, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008, 26:4708-4713.
12. Iten F, Muller B, Schindler C, et al. [(90)Yttrium-DOTA]-TOC response is associated with survival benefit in iodine-refractory thyroid cancer: long-term results of a phase 2 clinical trial. Cancer 2009, 115:2052-2062.
13. Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008, 26:4714-4719.
14. Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009, 27:1675-1684.
15. Ain KB, Lee C, Williams KD Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas. Thyroid 2007, 17:663-670.
16. Sherman SI, Wirth LJ, Droz JP, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 2008, 359:31-42. Motesanib Thyroid Cancer Study Group.
17. Argiris A, Agarwala SS, Karamouzis MV, Burmeister LA, Carty SE A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer. Invest New Drugs 2008, 26:183-188.
18. Mrozek E, Kloos RT, Ringel MD, et al. Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. J Clin Endocrinol Metab 2006, 91:2201-2204.
19. Woyach JA, Kloos RT, Ringel MD, et al. Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. J Clin Endocrinol Metab 2009, 94:164-170.
20. Pennell NA, Daniels GH, Haddad RI, et al. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid 2008, 18:317-323.
21. Cabanillas ME, Waguespack SG, Bronstein Y, et al. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J Clin Endocrinol Metab 2010, 95:2588-2595.
22. Tsimberidou AM, Vaklavas C, Wen S, et al. Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience. J Clin Endocrinol Metab 2009, 94:4423-4432.
23. Ain KB, Lee C, Holbrook KM, Dziba JM, Williams KD Phase II study of lenalidomide in distantly metastatic, rapidly progressive, and radioiodine-unresponsive thyroid carcinomas: preliminary results. Proc Am Soc Clin Oncol 2008, 26(suppl):6027. (abstr).
24. Yu XM, Lo CY, Chan WF, Lam KY, Leung P, Luk JM Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases. Clin Cancer Res 2005, 11:8063-8069.
25. Lennard CM, Patel A, Wilson J, et al. Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. Surgery 2001, 129:552-558.
26. Klein M, Vignaud JM, Hennequin V, et al. Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J Clin Endocrinol Metab 2001, 86:656-658.
27. Soh EY, Eigelberger MS, Kim KJ, et al. Neutralizing vascular endothelial growth factor activity inhibits thyroid cancer growth in vivo. Surgery 2000, 128:1059-1065.
28. Jo YS, Li S, Song JH, et al. Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J Clin Endocrinol Metab 2006, 91:3667-3670.
29. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009, 27:3312-3318.